Astrana Health, Inc.

Astrana Health, Inc. has achieved a new 52-week high, reflecting strong performance in the miscellaneous industry with a notable annual increase. The company, classified as small-cap, has demonstrated impressive financial health, including significant growth in net sales and profit, alongside a solid institutional holding percentage.

Astrana Health, Inc. has achieved a new 52-week high, reflecting its strong performance in the miscellaneous industry with a one-year return of 17.85%. The company, with a market cap of USD 1,362 million, is net-debt free and has demonstrated impressive growth metrics, including significant increases in net sales and profit.

Astrana Health, Inc. has achieved a new 52-week high, reflecting its strong performance in the miscellaneous industry. The company has demonstrated notable growth, with significant increases in net sales and profit. Its financial stability is underscored by being net-debt free and having substantial cash reserves.

Astrana Health, Inc. has achieved a new 52-week high, reflecting its strong performance in the miscellaneous industry as a small-cap entity. The company has shown resilience with a notable annual growth rate in net sales and profit, alongside a manageable debt level and significant institutional holdings.

Astrana Health, Inc. has achieved a new 52-week high, reflecting its strong market position in the miscellaneous industry. The company has shown resilience with modest performance growth, impressive increases in net sales and profit, and a solid balance sheet, supported by significant institutional holdings.

Astrana Health, Inc. has experienced a valuation adjustment, with a notably high price-to-earnings ratio of 67 compared to its peers. Its return on capital employed is 8.32%, and return on equity is 3.62%. The company's valuation metrics indicate a distinct market position within the industry.

Astrana Health, Inc. has recently adjusted its valuation, currently exhibiting a high P/E ratio of 67 compared to lower ratios of peers like Premier, Inc. and Select Medical Holdings Corp. Despite a recent weekly stock return of 22.53%, Astrana has underperformed over the past year with a return of -8.45%.

Astrana Health, Inc. has recently revised its evaluation amid market fluctuations, with its stock priced at $25.07. The company has experienced significant volatility over the past year, with a 52-week high of $34.80 and a low of $18.08. Short-term performance has been strong, outperforming the S&P 500.

Astrana Health, Inc. has recently adjusted its valuation, with a P/E ratio of 67 and a price-to-book value of 2.42. The company shows varied operational efficiency metrics, including an EV to EBIT of 27.49. Its performance contrasts with peers, highlighting the competitive landscape in the industry.

Astrana Health, Inc. faced significant stock volatility on November 7, 2025, with a notable decline. Over the past year, the company has underperformed the market, experiencing a substantial drop. Financial metrics show mixed results, including a high return on equity but declining net profit and a low debt-to-equity ratio.

Astrana Health, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, priced at $33.30, has shown significant volatility over the past year, with a high of $60.99 and a low of $21.20. Technical indicators present a mixed outlook, reflecting ongoing recovery efforts.

Astrana Health, Inc. has recently adjusted its valuation, with its stock price at $32.01. The company has faced a notable decline in stock performance over the past year, contrasting with broader market gains. Key financial metrics indicate a higher valuation compared to peers, reflecting differing market perceptions.